Drug Profile
CKD 387
Alternative Names: CKD-387Latest Information Update: 10 Jan 2023
Price :
$50
*
At a glance
- Originator CKD Pharmaceuticals
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 10 Jan 2023 CKD 387 is still in phase I trial for Type-2-diabetes-mellitus in South korea (NCT05673369)
- 04 Jan 2023 Chong Kun Dang Pharmaceutical initiates a phase I pharmacokinetics trial (In volunteers) in South korea (PO, Tablet) (NCT05673369)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in South Korea (PO, Tablet)